<DOC>
	<DOCNO>NCT01015534</DOCNO>
	<brief_summary>RATIONALE - Fractionated radiotherapy us high-energy photon kill , damage tumor cell . High daily dose temozolomide combine fractionated radiotherapy may make tumor cell sensible treatment . PURPOSE - This randomized phase II trial , assess patient brain metastasis solid tumor , whether whole brain radiotherapy ( WBRT ) plus temozolomide able improve result obtain WBRT .</brief_summary>
	<brief_title>Whole Brain Radiotherapy With Without Temozolomide Daily Fixed-dose Brain Metastases Treatment</brief_title>
	<detailed_description>Primary Outcome Measures - Objective Response Rates Secondary Outcome Measures - Survival Free Brain Metastases progression - Overall Survival - Systemic Side effect Objectives Primary - Compare objective response rate arm treatment Secondary - Compare survival free progression arm treatment - Compare Overall Survival arm treatment - Compare side effect</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>Karnofsky performance status ( KPS ) ≥ 50 Life expectancy ≥ 12 week Histologically confirm non lymphomatous solid tumor primary site Brain metastasis diagnose cranial MRI/CT . Extracranial metastasis primary tumor uncontrolled allow Hemoglobin ≥ 10 g/dl Absolute neutrophil count &gt; 1500/mm3 Platelet count ≥ 100,000/mm3 Blood urea nitrogen ( BUN ) ≤ 25 mg/dl , Serum creatinin ≤ 1.5 mg/dl Serum bilirubins ≤ 1.5 mg/dl , Alanine aminotransferase ( ALT ) Aspartate aminotransferase ( AST ) ≤ twice upper normal limit Exclusion Criteria Pregnant breast feed woman History allergic reaction iodinate contrast medium Inability swallow Systemic chemotherapy previous 3 week Oral chemotherapy previous 2 week Prior surgery , chemotherapy , radiotherapy brain neoplasm Meningeal carcinomatosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Brain metastasis</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Whole-brain radiotherapy</keyword>
	<keyword>Phase II trial</keyword>
</DOC>